State of the Art in Benign Hematology, Hemostasis and Thrombosis: 2026 Update in Emerging Therapeutics

This one-day, in-person symposium provides a state-of-the-art update on benign hematology, hemostasis, and thrombosis, highlighting emerging therapies and contemporary approaches to patient management. Designed for hematologists, oncologists, advanced practice providers, and other healthcare professionals involved in the care of patients with benign hematologic disorders, the program will focus on the latest evidence and evolving clinical practices in the field.

Key topics for 2026 include:

• Advances in venous thromboembolism (VTE) management, including pulmonary embolism, thrombosis in multiple myeloma, and novel anticoagulant strategies such as factor XI inhibitors.

• Interventional and device-related thrombosis, with updates on post-thrombotic syndrome and venous stenting.

• Hematologic complications of cancer therapy, including chemotherapy-induced cytopenias, the use of thrombopoietin receptor agonists, and immunotherapy-related complications such as hemophagocytic lymphohistiocytosis (HLH).

• Emerging concepts in immune thrombocytopenia (ITP), featuring patient-centered perspectives and novel therapeutic approaches.

Through expert-led presentations and interactive discussions, participants will explore challenging real-world management scenarios in thrombosis, cancer-associated cytopenias, and immune-mediated platelet disorders. The program will emphasize multidisciplinary care, emerging therapeutics, and the integration of new evidence into clinical practice. Ample time will be dedicated to audience questions and discussion with faculty, fostering practical learning and clinical application.

This symposium will be offered exclusively in person at Memorial Sloan Kettering’s Zuckerman Research Center. Please note that virtual participation will not be available. For information about accommodations, parking, directions, and planning your visit, please refer to our Visiting Us page. 

Following the conclusion of the symposium, participants will receive access to an online syllabus containing PDF copies of the faculty presentations.

1. Review contemporary management of VTE, including pulmonary embolism, myeloma-associated thrombosis, and factor XI inhibitors
2. Discuss management of device- and intervention-related thrombosis, including venous stents and cardiac thrombi
3. Identify and treat hematologic complications of cancer therapy, including cytopenias and immune-related syndromes
4. Evaluate emerging therapies and patient-centered approaches in immune thrombocytopenia (ITP)

Early Registration Rates (available through September 4, 2026)

• Physicians (MDs, PhDs, DOs): $250

• Advanced Practice Providers: $200

• Nurses and Other Healthcare Professionals: $150 

• Residents and Fellows*: $50

• Industry Professionals**: N/A

General Registration Rates (after September 4, 2026)

• Physicians (MDs, PhDs, DOs): $300

• Advanced Practice Providers: $250

• Nurses and Other Healthcare Professionals: $200 

• Residents and Fellows*: $100

• Industry Professionals**: $525

*Registration fees for Residents and Fellows are non-refundable. Please review our Cancellation Policy for more information.
**An industry professional is defined as any individual, irrespective of their provider type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company. Please review our Registration Policy for Industry Professionals for more information.

Discounted registration rates are available for select participant groups. Please note that early registration pricing is separate from other discounted registration categories. For additional information and eligibility requirements, please review our Registration Discounts Policy.

For details on our cancellation terms, please review our Cancellation Policy.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This live activity has been approved to offer the following credit types:

• AMA PRA Category 1 Credit(s)™

• ABIM Maintenance of Certification (MOC)

• ABPath Continuing Certification (CC)

Nursing continuing education credit is pending.

MSK Symposium Director

Jeffrey Zwicker, MD
Chief, Hematology Service



MSK Symposium Co-Director 

Avi Leader, MD
Assistant Attending, Hematology Service 

MSK Symposium Planning Committee

Jodi Mones, MD
Associate Program Director, Medical Oncology/Hematology Fellowship, Hematology Track;
Associate Attending, Hematology Service 

Cy Wilkins, MD
Assistant Attending, Hematology Service 

 Varun Iyengar, MD
Hematology-Oncology Fellow

Guest Faculty 

James Bussel, MD
Professor Emeritus of Pediatrics
Weill Cornell Medical College 

Marc Carrier, MD, MSc, FRCPC
Professor of Medicine
University of Ottawa

Adam Cuker, MD, MSTR
Professor of Medicine and of Pathology & Laboratory Medicine;
Chief, Section of Hematology
Perelman School of Medicine, University of Pennsylvania

Kristen Sanfilippo, MD, MPHS
Associate Professor, Division of Hematology
Washington University School of Medicine

MSK Faculty

Laurent Frenzel, MD, PhD
Visiting Investigator, Hematology Service
Memorial Sloan Kettering Cancer Center

Adie Friedman, MD
Attending, Interventional Radiology Service
Memorial Sloan Kettering Cancer Center

Anna Marcelli, MD
Associate Attending, Hematology Service
Memorial Sloan Kettering Cancer Center

Rekha Parameswaran, MD
Attending Member, Hematology Service
Memorial Sloan Kettering Cancer Center

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.